GW Pharmaceuticals (GWPH) popped to a near five-month high Monday after a rival drug from smaller biotech Zynerba Pharmaceuticals (ZYNE) failed in a midstage trial to treat epilepsy.
In early trading on the stock market today, GW Pharma lifted as much as 4.1% to a high last seen in late March. In recent trades, it was up 1.3%, near 119.20. Zynerba, though, plunged 59% to near 6.20.
